Occupational Therapists in Watervliet, MI Accepting Medicare
5 Occupational Therapists found. Showing 1 - 5
 Fikile Wendy Mpofu Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 400 Medical Park Dr, Watervliet, MI 49098 Phone: 269-463-2236 |
Tiffany Joy Shedlock, MSS, OTR/L, CAPS Occupational Therapist - Physical Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 400 Medical Park Dr, Watervliet, MI 49098 Phone: 269-463-6240 |
Angel N Page, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 400 Medical Park Dr, Watervliet, MI 49098 Phone: 269-615-4716 |
 Steven Vandenbosch, MS OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 400 Medical Park Dr, Watervliet, MI 49098 Phone: 269-463-3111 |
Eric Triezenberg, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 400 Medical Park Dr, Watervliet, MI 49098 Phone: 269-463-2331 |
News Archive
ev3 announces FDA approval of treatment for brain vascular disorder
ev3 today announced that its majority-owned subsidiary Micro Therapeutics has received pre-market application (PMA) approval from the U.S. Food and Drug Administration (FDA) to commercialize its Onyx Liquid Embolic System (Onyx) for the treatment of arterio-venous malformations (AVMs), a vascular disorder in the brain.
COVID-19 pandemic in Africa
In a New England Journal of Medicine "Perspective" published today, Wafaa El-Sadr, MD, MPH, global director of ICAP at Columbia University Mailman School of Public Health, and Jessica Justman, MD, ICAP's senior technical director, and associate professor of epidemiology, urge a coordinated global effort in the face of the COVID-19 pandemic, with "countries around the world [taking] concrete steps to assist Africa in staying ahead of the curve, even as they confront their own epidemics."
Chemistry researchers patent new method for making anti-leukemia compounds
Chemistry researchers at Oregon State University have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
Active Implants receives IDE approval to conduct NUsurface Meniscus Implant trial for knee osteoarthritis
Active Implants, the technology leader in cushion-bearing orthopedics for treatment of osteoarthritis, today announced it has received Investigational Device Exemption (IDE) approval to conduct a pivotal clinical trial of the NUsurface® Meniscus Implant in patients with knee osteoarthritis.
Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.
› Verified 5 days ago
Chiropractors
Occupational Therapists
Physical Therapists
Speech-Language Pathologists